QUE Oncology has announced the results of its Phase II trial of Q-122, a novel non-hormonal oral therapy for the treatment of vasomotor symptoms (commonly known as hot flashes/flushes and night sweats) in women taking endocrine therapy for breast cancer, have been published in The…
Source: hospitalhealth.com.au – Read more
Ventyx Bio Cardiovascular Drug’s Phase 2 Results Set Up Talks With a Big Pharma Firm
In a placebo-controlled mid-stage study, Ventyx Biosciences’ oral NLRP3 inhibitor led to rapid and sustained reductions in levels of a protein that’s an indicator of
